Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORION
2024-512769-16-00Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab + Olaparib maintenance with Durvalumab monotherapy maintenance (2 arms). Primary endpoint: Progression-free survival (PFS). Started Oct 2024; status: completed.
02
Drugs
durvalumabolaparib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-512769-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512769-16-00.